Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mandos LLC
Participants in Part C will receive adrabetadex until the investigator considers adrabetadex to no longer be beneficial to the participant, or the development program is discontinued.
Age
4–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
One of the following is required for inclusion into VTS301 Part C:
Has agreed to convert from the monthly dosing regimen used in the NIH phase 1/2a protocol to an every 2 weeks dosing regimen
The investigator has received prior written authorization from the sponsor for the participant to enter VTS301 Part C on an amended dose and/or regimen
Has received prior written authorization from Vtesse to enroll directly into Part C
Clareo Health | Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
